Media Alert

Contact: Chris Martin, IASLC Media Relations, cmartin@davidjamesgroup.com/630.670.2745

What: IASLC 2024 Latin America Conference on Lung Cancer

When: November 14-16, 2024

Where: Bogota, Columbia, Grand Hyatt Bogota

Meeting program: LALCA features three days of scientific sessions covering current topics in lung cancer research, including tobacco control, the role liquid biopsies play in cancer detection, anti-drug conjugates and immunotherapy.

Background: Lung cancer is the most common cancer in men and the second most frequent in women globally. In 2022, more than 2.4 million new cases and 1.8 million deaths from this disease were diagnosed, representing the leading cause of death from cancer. By 2030 it is anticipated that 541,000 new cases of lung cancer will be diagnosed in Latin America and the Caribbean, and mortality will exceed 454,000 cases in the same year. The most representative etiology remains smoking. However, about 26% of cases occur in people who have never smoked. Researchers and public health officials attribute these causes to environmental pollution, exposure to smoke from biomass, radon asbestos, tuberculosis, and probably the human papillomavirus. In Latin America, more than 70% of lung cancer cases are diagnosed at an advanced stage, mainly due to limitations in screening and diagnosis, as well as in the implementation of various staging procedures.

Press and Media: IASLC welcomes press attendance and coverage of LALCA 2024. To register to cover the meeting, visit https://www.lalca2024-iaslc.org/press-media. Registration allows you access to all meeting content.

To learn more about the meeting and to register, visit https://lalca2024-iaslc.org/